127 related articles for article (PubMed ID: 24600526)
41. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.
Heidenreich A; Pfister D; Porres D
J Urol; 2015 Mar; 193(3):832-8. PubMed ID: 25254935
[TBL] [Abstract][Full Text] [Related]
42. Prostate-specific antigen (PSA) bounce following salvage radiotherapy to the prostate bed in a patient with prostate cancer post-prostatectomy.
Rowe M; Adamson E; McGrane J
Int Cancer Conf J; 2020 Oct; 9(4):217-220. PubMed ID: 32904120
[TBL] [Abstract][Full Text] [Related]
43. [A case report: mucinous carcinoma of prostate].
Noma M; Mori N; Kobayashi Y; Hara T; Yamaguchi S
Hinyokika Kiyo; 2003 Oct; 49(10):591-3. PubMed ID: 14655602
[TBL] [Abstract][Full Text] [Related]
44. Race as an independent predictor of outcome after treatment for localized prostate cancer.
Sohayda CJ; Kupelian PA; Altsman KA; Klein EA
J Urol; 1999 Oct; 162(4):1331-6. PubMed ID: 10492191
[TBL] [Abstract][Full Text] [Related]
45. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study.
Garcia-Albeniz X; Chan JM; Paciorek A; Logan RW; Kenfield SA; Cooperberg MR; Carroll PR; Hernán MA
Eur J Cancer; 2015 May; 51(7):817-24. PubMed ID: 25794605
[TBL] [Abstract][Full Text] [Related]
46. Geriatric 8 screening of frailty in patients with prostate cancer.
Momota M; Hatakeyama S; Soma O; Tanaka T; Hamano I; Fujita N; Okamoto T; Yoneyama T; Yamamoto H; Imai A; Yoshikawa K; Yoneyama T; Hashimoto Y; Ohyama C
Int J Urol; 2020 Aug; 27(8):642-648. PubMed ID: 32500621
[TBL] [Abstract][Full Text] [Related]
47. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
48. Predictive factors and the important role of detectable prostate-specific antigen for detection of clinical recurrence and cancer-specific mortality following robot-assisted radical prostatectomy.
García-Barreras S; Rozet F; Nunes-Silva I; Srougi V; Sanchez-Salas R; Barret E; Galiano M; Cathelineau X
Clin Transl Oncol; 2018 Aug; 20(8):1004-1010. PubMed ID: 29243074
[TBL] [Abstract][Full Text] [Related]
49. Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors.
Chawla AK; Thakral HK; Zietman AL; Shipley WU
Urology; 2002 May; 59(5):726-31. PubMed ID: 11992848
[TBL] [Abstract][Full Text] [Related]
50. Should we replace the Gleason score with the amount of high-grade prostate cancer?
Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
[TBL] [Abstract][Full Text] [Related]
51. Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/ml. Or less.
D'Amico AV; Chen MH; Malkowicz SB; Whittington R; Renshaw AA; Tomaszewski JE; Samofalov Y; Wein A; Richie JP
J Urol; 2002 May; 167(5):2025-30; discussion 2030-1. PubMed ID: 11956431
[TBL] [Abstract][Full Text] [Related]
52. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
53. Adjuvant radiation, chemotherapy, and androgen deprivation therapy for pathologic stage D1 adenocarcinoma of the prostate.
Freeman JA; Lieskovsky G; Grossfeld G; Esrig D; Stein JP; Cook DW; Petrovich Z; Chen SC; Groshen S; Skinner DG
Urology; 1994 Nov; 44(5):719-25. PubMed ID: 7526528
[TBL] [Abstract][Full Text] [Related]
54. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
[TBL] [Abstract][Full Text] [Related]
55. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
56. Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation. The Prostate Cancer Study Group.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y
Int J Urol; 1999 May; 6(5):229-37; discussion 238-9. PubMed ID: 10375185
[TBL] [Abstract][Full Text] [Related]
57. Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer.
Petrovich Z; Lieskovsky G; Langholz B; Jozsef G; Streeter OE; Skinner DG
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):600-9. PubMed ID: 12062603
[TBL] [Abstract][Full Text] [Related]
58. A rare case of PSA-negative metastasized prostate cancer to the stomach with serum CEA and CA19-9 elevation: a case report.
Shindo K; Ohuchida K; Moriyama T; Kinoshita F; Koga Y; Oda Y; Eto M; Nakamura M
Surg Case Rep; 2020 Dec; 6(1):303. PubMed ID: 33263827
[TBL] [Abstract][Full Text] [Related]
59. [Mucinous adenocarcinoma of the prostate. A case report and analysis of the literature].
Watarai Y; Demura T; Togashi M; Ohashi N; Chikaraishi T; Hirano T; Fukazawa Y
Nihon Hinyokika Gakkai Zasshi; 1994 Aug; 85(8):1276-9. PubMed ID: 7523749
[TBL] [Abstract][Full Text] [Related]
60. Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density.
Allan RW; Sanderson H; Epstein JI
J Urol; 2003 Aug; 170(2 Pt 1):370-2. PubMed ID: 12853777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
